Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects.
Mushde ShakirPeter N van HartenAdriaan W HoogendoornAnne E WillemsDiederik E TenbackPublished in: Schizophrenia research (2024)
Switching APP to APM in long-term inpatients reduces the severity of various side effects, including movement disorders and metabolic side effects.